New vaginal suppository aims to clear HPV and reverse early cervical changes
NCT ID NCT07572396
First seen May 11, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tests an experimental vaginal suppository called Dysplasix in 45 women with high-risk HPV and mild cervical abnormalities (ASC-US or LSIL). Participants will use the suppository for 15 doses over 19 days and be monitored for two months. The goal is to see if the treatment can clear the HPV infection and reverse the cervical cell changes, while also checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prince of Wales Hospital
RECRUITINGShatin, New Territories, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.